1. Home
  2. KAPA

as 12-20-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

NYSE

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Founded: 2013 Country:
United States
United States
Employees: N/A City: LOS ANGELES
Market Cap: 20.2M IPO Year: 2024
Target Price: $9.00 AVG Volume (30 days): 92.8K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.26 EPS Growth: N/A
52 Week Low/High: $1.22 - $4.00 Next Earning Date: 11-14-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: